BillionToOne logo

BillionToOne

We push the boundaries of molecular diagnostics through quantitative technologies.

815 employees · est. 2016 · Menlo Park, United States

VS
Surfix logo

Surfix

Redefining Point-of-Care testing

38 employees · est. 2011 · Wageningen, The Netherlands

Surfix is the older company (2016 vs 2011); BillionToOne is the larger of the two.

Side-by-Side Comparison

BillionToOne Surfix
Founded
2016 2011 older
Headquarters
Menlo Park, United States Wageningen, The Netherlands
Employees
815 larger 38
Industry
Biotechnology, Health Care Biotechnology
Funding Stage
IPO Not tracked yet
Total Funding
$650.63M Not tracked yet
Funding Rounds
9 Not tracked yet
Services
Development and provision of advanced diagnostic tests, Quantification of disease-causing DNA fragments, Non-invasive prenatal and oncology testing solutions, Monitoring treatment response in cancer patients Not tracked yet
Target Customers
Healthcare Providers, Pregnant Women, Oncologists, Medical Researchers Not tracked yet
Taxonomy
Molecular Diagnostics, Precision Diagnostics, DNA Quantification, Molecular Counting Technology, Disease Detection, Prenatal Testing, Single-gene Disorder Detection, Non-invasive Testing, Blood Test Innovation, Affordable Healthcare Solutions, Patent-pending Technology, Risk Reduction In Diagnostics, Biotechnology Innovation Surfix Diagnostics, Diagnostics, Photonic Diagnostics Platform, Biosensor Technology, Cancer Detection, Early Detection, Liquid Biopsy, Microfluidics, Immunoassays, Molecular Diagnostics, Nanocoatings, Point-of-Care Testing, Biofunctionalization, Lab-on-a-Chip, Bioreceptor
Website
billiontoone.com surfixdx.com
BillionToOne logo

About BillionToOne

BillionToOne, founded in 2016, is a pioneering entity in the Biotechnology and Health Care industries, headquartered in the United States. The company is renowned for its commitment to enhancing the accuracy, efficiency, and accessibility of molecular diagnostics, encapsulated in their slogan: "We p...

Surfix logo

About Surfix

Surfix Diagnostics, founded in 2011 and headquartered in The Netherlands, is a biotechnology startup with the goal of providing easy-to-use, reliable, and sensitive diagnostic tests for the early detection and monitoring of cancer. The company's photonic diagnostics platform integrates six cutting-e...

Be first to know when either one moves

Funding rounds, hiring surges, leadership changes and stack switches at BillionToOne and Surfix — tracked continuously, sent the day they land.

Watch both — free

Funding, hiring, leadership and stack changes at BillionToOne and Surfix — by email.

Frequently Asked Questions

BillionToOne — We push the boundaries of molecular diagnostics through quantitative technologies.. Surfix — Redefining Point-of-Care testing. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
BillionToOne has raised $650.63M while Surfix has raised undisclosed funding.
BillionToOne and Surfix operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare BillionToOne with someone else

Start typing a company name or domain.

One analytics cookie (Google Analytics). Cookie Policy